Announcements Trials

Browse Landscape

Phase

Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 271 Breast 166 Sarcoma 92 Other hematologic neoplasm 70 Genitourinary 35 Gastrointestinal 34 Gynecologic 30 CNS 30 Plasma cell 22 Thoracic 10 Head & Neck 9 Other solid neoplasm 6 Endocrine 6 Myeloid 5 Tumor-Agnostic 3 Dermatologic 3 NET 1 Classical hematology 1

Conditions

Neuroendocrine Tumors 1 Neoplasms 1 Neoplasm Metastasis 1

Interventions

lutetium Lu 177 dotatate 18 Everolimus 13 Temozolomide 12 Nivolumab 10 pembrolizumab 9 cabozantinib 8 Capecitabine 8 Sunitinib 7 lenvatinib 5 Magnetic Resonance Spectroscopy 5 Etoposide 5 lanreotide 4 gallium Ga 68 dotatate 4 Specimen Handling 4 Ipilimumab 4 Cisplatin 4 Carboplatin 4 177Lu-octreotide, DOTA(0)-Tyr(3)- 4 telotristat ethyl 3 surufatinib 3 pazopanib 3 avelumab 3 Octreotide 3 Injections 3 Fluorodeoxyglucose F18 3 Cyclophosphamide 3 Bevacizumab 3 sintilimab 2 fosbretabulin 2 fludarabine 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Doxorubicin × NET × Clear all

NCT01678664 2024-09-25

EVACEL

Federation Francophone de Cancerologie Digestive

Phase 2 Completed

74 enrolled 10 charts

Neoplasm Metastasis, Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡